Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study

• Published in: European journal of cancer (1990) 2020-10, Vol.138, p.125-132
• Main Authors: Salzmann, Martin, Leiter, Ulrike, Loquai, Carmen, Zimmer, Lisa, Ugurel, Selma, Gutzmer, Ralf, Thoms, Kai-Martin, Enk, Alexander H., Hassel, Jessica C.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Apoptosis; Cancer; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - mortality; Cell death; Cemiplimab; Cutaneous squamous cell carcinoma; Disease control; Female; Humans; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Inhibitors; L-Lactate dehydrogenase; L-Lactate Dehydrogenase - blood; Lactate dehydrogenase; Lactic acid; Male; Metastases; Middle Aged; Monoclonal antibodies; Patients; PD-1; PD-1 protein; Pembrolizumab; Proteins; Remission; Retrospective Studies; Serum levels; Skin cancer; Skin neoplasms; Skin Neoplasms - drug therapy; Skin Neoplasms - mortality; Squamous cell carcinoma; Survival; Targeted cancer therapy; Therapy; Toxicity
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2020.07.029

Cutaneous squamous cell carcinoma (cSCC) is one of the most common malignancies of the skin. Even though most patients are sufficiently treated by surgical resection, some will eventually metastasize and need systemic therapy. Phase I and II studies have shown efficacy for programmed cell death protein 1 (PD-1) inhibitors, but cohort sizes are low and real-world data especially on long-term outcome are pending. Patients from six German skin cancer centers treated with PD-1 inhibitors (pembrolizumab, nivolumab or cemiplimab) for advanced cSCC were retrospectively studied. Internal patient records were analyzed for clinical outcome including response, progression-free survival (PFS), overall survival (OS) and toxicity. Of 46 evaluable patients (median age: 76 years), the overall response rate (RR) was 58.7%, including 15.2% with complete response. The disease control rate was 80.4%. Both median PFS and OS were not reached, Kaplan–Meier estimated 1-year PFS was 58.8%. Patients responding to therapy showed durable remission. Response was independent of the PD-1 inhibitor used and also independent of the presence of distant metastases vs. locally advanced disease. Two predictive factors were found: Patients with primaries located on the leg had a poorer therapy outcome and patients with high lactate dehydrogenase serum levels at baseline. Treatment was overall tolerated well, with less than 10% of patients discontinuing therapy due to toxicity. PD-1 inhibitors fulfill the need for an efficient systemic therapy for advanced cSCC and should be the new standard of care. With high RRs and durable disease control, neoadjuvant and adjuvant regimens should be evaluated. •Patients treated with programmed cell death protein 1 inhibitorsfor advanced cutaneous squamous cell carcinoma were retrospectively analyzed.•An extraordinary efficacy in routine clinical use was found, comparable to clinical trials.•The response rate was 59%, disease control rate was 80%.•Efficacy was high in both locally advanced and metastasized disease.•The treatment was very well tolerated in the mostly elderly patients.